Ideaya Biosciences announced initiation of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Stifel disagrees with negative reaction in Ideaya shares after Amgen data
- Ideaya has positive read from Amgen PRMT5 data, says Oppenheimer
- Ideaya Biosciences selects Werner Helicase Inhibitor Development DC with GSK
- Ideaya Biosciences participates in a conference call with JPMorgan
- Ideaya Biosciences granted IDE161 fast track designation in second indication